Search results
Results from the WOW.Com Content Network
Capecitabine, sold under the brand name Xeloda among others, is a anticancer medication used to treat breast cancer, gastric cancer and colorectal cancer. [3] For breast cancer it is often used together with docetaxel. [4] It is taken by mouth. [4] Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. [4]
Last week, Israel-based Teva Pharmaceuticals' generic product portfolio received a major boost after the Food and Drug Administration approved the company's generic version of Xeloda, a cancer drug.
This is an accepted version of this page This is the latest accepted revision, reviewed on 16 February 2025. Cancer that originates in mammary glands Medical condition Breast cancer An illustration of breast cancer Specialty Surgical oncology Symptoms A lump in a breast, a change in breast shape, dimpling of the skin, fluid from the nipple, a newly inverted nipple, a red scaly patch of skin on ...
In March 2007, the U.S. Food and Drug Administration (FDA) approved lapatinib in combination therapy for breast cancer patients already using capecitabine (Xeloda). [4] [5] In January 2010, Tykerb received accelerated approval for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor and for whom hormonal therapy is ...
Tucatinib is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for the treatment of adults with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. [3]
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.
Triple-negative breast cancer comprises 15–20% of all breast cancer cases [3] and affects more young women or women with a mutation in the BRCA1 gene than other breast cancers. [4] Triple-negative breast cancers comprise a very heterogeneous group of cancers. TNBC is the most challenging breast cancer type to treat. [5]
CAPOX (also called XELOX [1]) is a chemotherapy regimen consisting of capecitabine (trade name Xeloda) combined with oxaliplatin. [ 2 ] [ 3 ] Xelox regime operates in 3-week cycles, usually with 8 cycles in total; Xeloda is taken orally twice daily for two weeks, while oxaliplatin is administered by IV on the first day of the cycle; there is a ...